592-88-1

Applied Filters:

Keyword:'592-88-1'

Showing 1-2 of 2 results for "592-88-1" within Papers

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.

Timo Mäkikallio et al.

Lancet (London, England), 388(10061), 2743-2752 (2016-11-05)

Coronary artery bypass grafting (CABG) is the standard treatment for revascularisation in patients with left main coronary artery disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. We aimed to compare PCI and CABG for treatment

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Hertzel C Gerstein et al.

Lancet (London, England), 394(10193), 121-130 (2019-06-14)

Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse

Page 1 of 1